Clearmind Medicine Inc. (CMND) — Clearmind Medicine said its independent Data and Safety Monitoring Board reviewed the accumulated safety data and cleared the CMND-100 Phase I/IIa alcohol-use-disorder trial to proceed to its next stage.
The decision followed the positive second-cohort safety results reported in February. Advancing past the DSMB checkpoint keeps the non-hallucinogenic MEAI-based candidate moving through early clinical development.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.